Blueprint Medicines Corp (BPMC) — Cash Flow-to-Debt Ratio
Blueprint Medicines Corp (BPMC) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2025, meaning its operating cash flow of $-54.48 Million could theoretically repay 0% of its total liabilities ($853.47 Million) in one year. Explore Blueprint Medicines Corp long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Blueprint Medicines Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Blueprint Medicines Corp across 12 annual periods. Also explore balance sheet size of Blueprint Medicines Corp for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Blueprint Medicines Corp (2013–2024)
Year-by-year debt coverage analysis for Blueprint Medicines Corp. For market capitalisation and broader financial context, see Blueprint Medicines Corp (BPMC) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.22x | $-192.59 Million | $881.15 Million | ▲ +54.0% |
| 2023 | -0.48x | $-436.85 Million | $918.64 Million | ▲ +20.9% |
| 2022 | -0.60x | $-502.28 Million | $835.23 Million | ▲ +43.3% |
| 2021 | -1.06x | $-298.65 Million | $281.49 Million | ▼ -168.1% |
| 2020 | 1.56x | $387.04 Million | $248.31 Million | ▲ +236.4% |
| 2019 | -1.14x | $-278.01 Million | $243.34 Million | ▲ +20.9% |
| 2018 | -1.44x | $-175.01 Million | $121.11 Million | ▼ -10.6% |
| 2017 | -1.31x | $-119.86 Million | $91.77 Million | ▼ -271.5% |
| 2016 | -0.35x | $-24.51 Million | $69.72 Million | ▲ +61.2% |
| 2015 | -0.91x | $-31.68 Million | $34.92 Million | ▲ +62.9% |
| 2014 | -2.44x | $-35.40 Million | $14.50 Million | ▲ +27.7% |
| 2013 | -3.38x | $-19.02 Million | $5.63 Million | — |